Immuneering (IMRX) announced the appointment of Thomas Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Strategic Advances and Positive Outlook Boost Buy Rating and Price Target
- Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP
- Immuneering files to sell 9.18M shares of Class A common stock for holders
- Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
- Immuneering announces clinical supply agreement with Eli Lilly